The Oncology Institute Reports 20% YoY Revenue Growth in Q2 2025.

• The Oncology Institute reports 20% YoY revenue growth in Q2 2025. • Pharmacy business grows 40% YoY. • Value-based business adds 50,000 new capitated lives. • Plans to expand partnership into new Florida regions.

The Oncology Institute, Inc. (NASDAQ: TOI) reported robust financial performance for the second quarter of 2025, with a 21.5% year-over-year (YoY) increase in revenue. The company's pharmacy business grew by over 40% YoY, while the value-based business added 50,000 new capitated lives. The company also outlined plans to expand its partnership into new Florida regions.

Key financial highlights include a gross profit of $17.5 million, up 34.4% YoY, and an adjusted EBITDA of $(4.1) million, representing a significant improvement from the $(8.7) million reported in the same period last year. The company's net loss for the quarter was $17.0 million.

The company's CEO, Daniel Virnich, attributed the strong performance to the exceptional growth in the pharmacy business and the addition of new capitated lives. He also noted the ongoing expansion into new Florida regions with a major health plan, which is expected to double the covered lives for that payor.

The Oncology Institute reaffirmed its 2025 revenue guidance of $460 to $480 million and expects to achieve the higher end of this range. The company also anticipates reaching adjusted EBITDA positivity by the end of 2025, with a Q3 2025 adjusted EBITDA projection of $(2.5) to $(3.5) million.

The company's stock price has been performing well, with the current average analyst rating on the shares being "buy" and the median 12-month price target of $7.00, about 41.3% above its August 12 closing price of $4.11.

References:

[1] https://www.tradingview.com/news/reuters.com,2025:newsml_PLX6D1E76:0-the-oncology-institute-s-q2-revenue-up-21-5-beats-estimates/
[2] https://www.stocktitan.net/news/TOI/the-oncology-institute-reports-second-quarter-2025-financial-results-x0gr7w9z1eg1.html